JCEM:三甲基赖氨酸与射血分数保留的心力衰竭和心血管事件的关系

2022-09-06 MedSci原创 MedSci原创

血浆三甲基赖氨酸浓度与HFpEF呈正相关,较高的血浆三甲基赖氨酸表明心血管事件风险增加。

肉碱与心脏能量代谢和心力衰竭有关,但其前体-三甲基赖氨酸和γ-丁甜菜碱(GBB)与射血分数保留心力衰竭(HFpEF)之间的关系尚不清楚。

近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究的主要目的是评估亚洲人群中三甲基赖氨酸相关代谢物与HFpEF之间的关系。

该研究的横截面部分探究了血浆三甲基赖氨酸相关代谢物与HFpEF之间的关系,同时采用前瞻性队列设计探究了HFpEF与心血管事件发生之间的关系。该研究纳入了1000名非心力衰竭(非HF)患者和1413名HFpEF患者。研究人员采用液相色谱-质谱法测定了受试者血浆中肉碱、GBB、三甲基赖氨酸和三甲胺-n-氧化物(TMAO)的浓度。

HFpEF患者血浆GBB、三甲基赖氨酸均升高。在调整传统危险因素和肾功能后,三甲基赖氨酸与HFpEF显著相关,而与GBB无关。三甲基赖氨酸第4个四分位与第1个四分位的比值比为1.57(95%CI为1.09-2.27;趋势P<0.01)。三甲基赖氨酸对数值每个SD增量的ORs为1.26(95%CI为1.08-1.47)。血浆TMAO(相互作用P=0.024)和eGFR(相互作用P=0.024)修饰了三甲基赖氨酸与HFpEF之间的相关性。三甲基赖氨酸的加入可以提高多变量模型下的诊断价值。在HFpEF患者的前瞻性研究中,较高的血浆三甲基赖氨酸与心血管事件的风险增加相关。

由此可见,血浆三甲基赖氨酸浓度与HFpEF呈正相关,较高的血浆三甲基赖氨酸表明心血管事件风险增加。

原始出处:

Haoran Wei,et al.Association of Systemic Trimethyllysine with Heart Failure with Preserved Ejection Fraction and Cardiovascular Events.JCEM.2022.https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgac519/6691858

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
    2023-02-10 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
    2023-02-14 achengzhao
  7. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]
    2022-09-08 陈吴1239
  8. [GetPortalCommentsPageByObjectIdResponse(id=1778253, encodeId=ffde1e78253ff, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Feb 10 09:50:10 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643817, encodeId=6ea4164381e56, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jul 02 08:50:10 CST 2023, time=2023-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118407, encodeId=5da8211840ecc, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>与<a href='/topic/show?id=6d334680307' target=_blank style='color:#2F92EE;'>#射血分数保留心力衰竭#</a>和<a href='/topic/show?id=38c451e4317' target=_blank style='color:#2F92EE;'>#心血管事件#</a>的关系<a href='/topic/show?id=072c5088466' target=_blank style='color:#2F92EE;'>#心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸), TopicDto(id=46803, encryptionId=6d334680307, topicName=射血分数保留心力衰竭), TopicDto(id=51743, encryptionId=38c451e4317, topicName=心血管事件), TopicDto(id=50884, encryptionId=072c5088466, topicName=心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Mar 09 04:26:45 CST 2023, time=2023-03-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1746335, encodeId=289e1e4633591, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Sat Jul 01 01:50:10 CST 2023, time=2023-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768927, encodeId=d7b81e689277c, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Dec 26 06:50:10 CST 2022, time=2022-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063635, encodeId=eeb320636355b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Feb 14 06:50:10 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552555, encodeId=ce11155255559, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592179, encodeId=4bea15921e995, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Thu Sep 08 05:50:10 CST 2022, time=2022-09-08, status=1, ipAttribution=)]

相关资讯

Radiology:女性和男性的胸主动脉直径和心血管事件的发生率及死亡率之间的关系

尽管胸主动脉扩张是临床实践中经常发现的问题,但在人群中很少有关于其对主要心血管疾病长期预后的作用的纵向数据。

ESC 2022:长期依洛尤单抗治疗可进一步减少心血管事件(FOURIER-OLE研究)

8月29日,ESC 2022年会HOT LINE8专场发布了FOURIER-OLE试验的结果。研究显示,长期应用依洛尤单抗(evolocumab)降低低密度脂蛋白胆固醇(LDL-C)的安全性和耐受性均

NEJM:单片复方制剂能降低心肌梗死后患者心血管事件复发(SECURE试验)

心肌梗死是当前全球心衰最常见、最重要的病因之一。中国心梗后患者发病率,全因死亡率、心血管事件发生率和再住院率较高 ,这与该类患者疾病的严重性有关,也与治疗手段是否及时、恰当以及心脏科医师的疾病预防和治

JAHA:脉搏波形参数可预测心血管事件

在基于人群的队列中,一些波形参数与MACE独立相关。增强指数和反射幅度略微提高了风险预测效能,尤其是在心血管风险较低的患者中。

JAHA:晚期糖基化终产物与心血管事件风险的关系

在老年人群中α-二羰基衍生的AGEs与CVD相关,但在更健康的中年/老年人群中则无关。该研究的结果表明,AGEs仅在显著的二羰基和氧化应激条件下才可能发挥有害的心血管作用。

Hematol Oncol:诊断为弥漫性大 B 细胞淋巴瘤并接受蒽环类药物治疗的患者心血管事件和死亡率的危险因素

老年患者、糖尿病患者和疾病晚期患者发生CVE的风险最高,后续研究应重点关注这些高危患者群体中这一常见并发症的监测和预防措施